Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Orelabrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InnoCare's Orelabrutinib Data Presented At ESMO Congress 2024
    InnoCare's Orelabrutinib Data Presented At ESMO Congress 2024

    13 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913406407/en

    BUSINESSWIRE
    13 Sep 2024
    Share Share
    InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
    InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib

    12 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240312903691/en

    BUSINESSWIRE
    12 Mar 2024
    Share Share
    InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib
    InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib

    26 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231026397005/en

    BUSINESSWIRE
    26 Oct 2023
    Share Share
    Study Result of Orelabrutinib in Patients with r/r MZL Published
    Study Result of Orelabrutinib in Patients with r/r MZL Published

    12 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230912051988/en

    BUSINESSWIRE
    12 Sep 2023
    Share Share
    Latest Data of InnoCare's Orelabrutinib Presented at the 17th (ICML)
    Latest Data of InnoCare's Orelabrutinib Presented at the 17th (ICML)

    15 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230615639879/en

    BUSINESSWIRE
    15 Jun 2023
    Share Share
    Clinical Study Result of Orelabrutinib in Patients with R/R MCL
    Clinical Study Result of Orelabrutinib in Patients with R/R MCL

    01 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230501005058/en

    BUSINESSWIRE
    01 May 2023
    Share Share